Evidence map›Paper›PMID 33517534›Full record

Trial reportClinical research in cardiology : official journal of the German Cardiac Society2021

Ten-year all-cause death following percutaneous or surgical revascularization in patients with prior cerebrovascular disease: insights from the SYNTAX Extended Survival study.

Rutao Wang, Kuniaki Takahashi, Scot Garg, Daniel J F M Thuijs, Arie Pieter Kappetein, Michael J Mack, Marie-Claude Morice, Friedrich-Wilhelm Mohr, Nick Curzen, Piroze Davierwala and 6 more

2 registry-linked trialsOpen access · hybridAbstract readControlled Clinical TrialMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Clinical research in cardiology : official journal of the German Cardiac Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00114972 phase3unknown statusnot on this map

SYNTAX Study: SYNergy Between PCI With TAXUS and Cardiac Surgery

TypeinterventionalSponsorBoston Scientific CorporationRan2005 to 2012Enrolled1,800ConditionsCoronary Artery DiseaseArmsPolymer-based Paclitaxel-Eluting TAXUS Express2-SR Stent, Coronary Artery Bypass Surgery
NCT03417050 completednot on this map

Synergy Between PCI With TAXUS and Cardiac Surgery: SYNTAX Extended Survival

TypeobservationalSponsorErasmus Medical CenterRan2016 to 2019Enrolled2,636ConditionsCoronary Artery DiseaseArmsNo intervention will take place for this retrospective and observational study.
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Observational
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 12 institutions in 8 countries.

Rutao Wang *Department of Cardiology, Xijing Hospital, Xi'an, China.
Kuniaki Takahashi *Department of Cardiology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Scot GargEast Lancashire Hospitals NHS Trust, Blackburn, Lancashire, UK.
Daniel J F M ThuijsDepartment of Cardiothoracic Surgery, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Arie Pieter KappeteinDepartment of Cardiothoracic Surgery, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Michael J MackDepartment of Cardiothoracic Surgery, Baylor University Medical Center, Dallas, TX, USA.
Marie-Claude MoriceDépartement of Cardiologie, Hôpital Privé Jacques Cartier, Générale de Santé Massy, Massy, France.
Friedrich-Wilhelm MohrUniversity Department of Cardiac Surgery, Heart Centre Leipzig, Leipzig, Germany.
Nick CurzenCardiology Department, University Hospital Southampton, Southampton, UK.
Piroze DavierwalaUniversity Department of Cardiac Surgery, Heart Centre Leipzig, Leipzig, Germany.
Milan MilojevicDepartment of Cardiothoracic Surgery, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Robert Jan van GeunsDepartment of Cardiology, Radboud UMC, Nijmegen, The Netherlands.
Stuart J HeadDepartment of Cardiothoracic Surgery, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Yoshinobu OnumaDepartment of Cardiology, National University of Ireland Galway, University Road, Galway, H91 TK33, Ireland.
David R HolmesDepartment of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Patrick W SerruysDepartment of Cardiology, National University of Ireland Galway, University Road, Galway, H91 TK33, Ireland. patrick.w.j.c.serruys@gmail.com.ORCID http://orcid.org/0000-0002-9636-1104
Erasmus University Rotterdam · NLLeipzig Heart Institute · DERadboud University Nijmegen · NLBaylor University Medical Center · USEast Lancashire Hospitals NHS Trust · GBHôpital Privé Jacques Cartier · FRInstitute for Cardiovascular Diseases of Vojvodina · RSMayo Clinic in Arizona · USNational University of Ireland · IEOllscoil na Gaillimhe – University of Galway · IEUniversity Hospital Southampton NHS Foundation Trust · GBUniversity of Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCoronary bypass artery grafting (CABG) has a higher procedural risk of stroke than percutaneous coronary intervention (PCI), but may offer better long-term survival. The optimal revascularization strategy for patients with prior cerebrovascular disease (CEVD) remains unclear. METHODS AND

resultsThe SYNTAXES study assessed the vital status out to 10 year of patients with three-vessel disease and/or left main coronary artery disease enrolled in the SYNTAX trial. The relative efficacy of PCI vs. CABG in terms of 10 year all-cause death was assessed according to prior CEVD. The primary endpoint was 10 year all-cause death. The status of prior CEVD was available in 1791 (99.5%) patients, of whom 253 patients had prior CEVD. Patients with prior CEVD were older and had more comorbidities (medically treated diabetes, insulin-dependent diabetes, metabolic syndrome, peripheral vascular disease, chronic obstructive pulmonary disease, impaired renal function, and congestive heart failure), compared with those without prior CEVD. Prior CEVD was an independent predictor of 10 year all-cause death (adjusted HR: 1.35; 95% CI: 1.04-1.73; p = 0.021). Patients with prior CEVD had a significantly higher risk of 10 year all-cause death (41.1 vs. 24.1%; HR: 1.92; 95% CI: 1.54-2.40; p < 0.001). The risk of 10 year all-cause death was similar between patients receiving PCI or CABG irrespective of the presence of prior CEVD (p

conclusionPrior CEVD was associated with a significantly increased risk of 10 year all-cause death which was similar in patients treated with PCI or CABG. These results do not support preferential referral for PCI rather than CABG in patients with prior CEVD.

trial registrationSYNTAX: ClinicalTrials.gov reference: NCT00114972. SYNTAX Extended Survival: ClinicalTrials.gov reference: NCT03417050.

Indexed as

AgedCause of DeathCerebrovascular DisordersCoronary Artery BypassCoronary Artery DiseaseFemaleFollow-Up StudiesHumansMaleMiddle AgedMyocardial RevascularizationPercutaneous Coronary InterventionRisk FactorsCABGCerebrovascular diseaseLeft main coronary artery diseasePCIThree-vessel disease

Identifiers

PMID33517534
PMCPMC8484131
OpenAlexW3127900461

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.